Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $4.6 million.

  • Northwest Biotherapeutics' Cash & Current Investments rose 55.15% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 32.67%. This contributed to the annual value of $2.2 million for FY2024, which is 2.30% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Cash & Current Investments stood at $4.6 million, which was up 5.65% from $4.3 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Cash & Current Investments high stood at $15.2 million for Q4 2021, and its period low was $1.4 million during Q2 2023.
  • Over the past 3 years, Northwest Biotherapeutics' median Cash & Current Investments value was $2.9 million (recorded in 2024), while the average stood at $3.5 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 877.49% in 2021, then slumped by 70.52% in 2023.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Cash & Current Investments stood at $15.2 million in 2021, then slumped by 54.08% to $7.0 million in 2022, then slumped by 69.48% to $2.1 million in 2023, then rose by 2.30% to $2.2 million in 2024, then soared by 55.15% to $4.6 million in 2025.
  • Its Cash & Current Investments was $4.6 million in Q3 2025, compared to $4.3 million in Q2 2025 and $2.8 million in Q1 2025.